Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | proteasome A-type and B-type family protein | 0.12 | 1 | 1 |
Entamoeba histolytica | proteasome subunit beta type 5 precursor, putative | 0.12 | 1 | 1 |
Toxoplasma gondii | ICE family protease (caspase) p20 domain-containing protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | caspase 8 | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma cruzi | metacaspase, putative | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Plasmodium falciparum | metacaspase 1 | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | cathepsin b | 0.0181 | 0.0067 | 0.0067 |
Brugia malayi | cathepsin B-like cysteine proteinase | 0.0181 | 0.0067 | 0.0067 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Mycobacterium ulcerans | proteasome PrcB | 0.12 | 1 | 0.5 |
Brugia malayi | Cell death protein 3 precursor | 0.0785 | 0.5955 | 0.5955 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.12 | 1 | 1 |
Echinococcus granulosus | apoptotic protease activating factor 1 | 0.0413 | 0.2326 | 0.2326 |
Onchocerca volvulus | Cell death protein 3 homolog | 0.0785 | 0.5955 | 1 |
Trypanosoma cruzi | metacaspase, putative | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma cruzi | metacaspase, putative | 0.0373 | 0.1935 | 0.1935 |
Echinococcus granulosus | caspase | 0.0734 | 0.5458 | 0.5458 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0181 | 0.0067 | 0.0067 |
Trypanosoma cruzi | proteasome subunit beta type-5, putative | 0.12 | 1 | 1 |
Echinococcus multilocularis | caspase | 0.0734 | 0.5458 | 0.5458 |
Trichomonas vaginalis | Family T1, proteasome beta subunit, threonine peptidase | 0.12 | 1 | 1 |
Trypanosoma brucei | Metacaspase-4 | 0.0373 | 0.1935 | 0.1935 |
Plasmodium vivax | hypothetical protein, conserved | 0.0373 | 0.1935 | 0.1935 |
Loa Loa (eye worm) | hypothetical protein | 0.0413 | 0.2326 | 0.2326 |
Loa Loa (eye worm) | hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma brucei | metacaspase | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | caspase 3 | 0.0362 | 0.1829 | 0.1829 |
Echinococcus multilocularis | proteasome (prosome, macropain) | 0.12 | 1 | 1 |
Leishmania major | proteasome beta 5 subunit, putative | 0.12 | 1 | 1 |
Schistosoma mansoni | caspase-3 (C14 family) | 0.0734 | 0.5458 | 0.5458 |
Loa Loa (eye worm) | hypothetical protein | 0.0785 | 0.5955 | 0.5955 |
Echinococcus granulosus | cathepsin b | 0.0181 | 0.0067 | 0.0067 |
Plasmodium falciparum | proteasome subunit beta type-5 | 0.12 | 1 | 1 |
Giardia lamblia | Proteasome subunit beta type 5 precursor | 0.12 | 1 | 0.5 |
Schistosoma mansoni | subfamily C14A unassigned peptidase (C14 family) | 0.0373 | 0.1935 | 0.1935 |
Onchocerca volvulus | 0.0413 | 0.2326 | 0.3905 | |
Echinococcus granulosus | caspase 3 apoptosis cysteine peptidase | 0.0734 | 0.5458 | 0.5458 |
Mycobacterium tuberculosis | Proteasome beta subunit PrcB; assembles with alpha subunit PrcA. | 0.12 | 1 | 0.5 |
Trypanosoma brucei | metacaspase MCA2 | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | caspase 2 | 0.0785 | 0.5955 | 0.5955 |
Brugia malayi | mucosa associated lymphoid tissue lymphoma translocation protein 1 | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma cruzi | metacaspase 5, putative | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | cathepsin b | 0.0181 | 0.0067 | 0.0067 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0181 | 0.0067 | 0.0067 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma cruzi | metacaspase, putative | 0.0373 | 0.1935 | 0.1935 |
Plasmodium vivax | proteasome subunit beta type-5, putative | 0.12 | 1 | 1 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma brucei | metacaspase MCA3 | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma brucei | proteasome subunit beta type-5, putative | 0.12 | 1 | 1 |
Echinococcus granulosus | caspase 3 | 0.0362 | 0.1829 | 0.1829 |
Trypanosoma cruzi | metacaspase 5, putative | 0.0373 | 0.1935 | 0.1935 |
Leishmania major | metacaspase, putative | 0.0373 | 0.1935 | 0.1935 |
Plasmodium vivax | metacaspase 1, putative | 0.0373 | 0.1935 | 0.1935 |
Toxoplasma gondii | proteasome subunit beta type, putative | 0.12 | 1 | 1 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Schistosoma mansoni | proteasome catalytic subunit 3 (T01 family) | 0.12 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0181 | 0.0067 | 0.0067 |
Plasmodium falciparum | metacaspase-like protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus granulosus | proteasome prosome macropain | 0.12 | 1 | 1 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Mycobacterium leprae | proteasome (beta subunit) PrcB | 0.12 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0413 | 0.2326 | 0.2326 |
Brugia malayi | hypothetical protein | 0.0413 | 0.2326 | 0.2326 |
Trypanosoma brucei | metacaspase 5, putative | 0.0373 | 0.1935 | 0.1935 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0181 | 0.0067 | 0.0067 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0181 | 0.0067 | 0.0067 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Toxoplasma gondii | ICE family protease (caspase) p20 domain-containing protein | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus granulosus | caspase 8 | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus granulosus | caspase 2 | 0.0785 | 0.5955 | 0.5955 |
Toxoplasma gondii | ICE family protease (caspase) p20 domain-containing protein | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | apoptotic protease activating factor 1 | 0.0413 | 0.2326 | 0.2326 |
Schistosoma mansoni | caspase-7 (C14 family) | 0.0734 | 0.5458 | 0.5458 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0181 | 0.0067 | 0.0067 |
Trichomonas vaginalis | Clan CD, family C14, metacaspase-like cysteine peptidase | 0.0373 | 0.1935 | 0.1935 |
Echinococcus multilocularis | caspase 3, apoptosis cysteine peptidase | 0.0734 | 0.5458 | 0.5458 |
Schistosoma mansoni | caspase-7 (C14 family) | 0.0785 | 0.5955 | 0.5955 |
Echinococcus granulosus | cathepsin b | 0.0181 | 0.0067 | 0.0067 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Effect (functional) | = 18.5 | Estrogenic activity in uterotrophic assay in immature mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 25.5 | Estrogenic activity in uterotrophic assay in immature mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 35.8 | Estrogenic activity in uterotrophic assay in immature mice at 50.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 39.5 | Estrogenic activity in uterotrophic assay in immature mice at 125 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 42.6 | Estrogenic activity in uterotrophic assay in immature mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 45.7 | Estrogenic activity in uterotrophic assay in immature mice at 50.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 51 | Estrogenic activity in uterotrophic assay in immature mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 52.3 | Estrogenic activity in uterotrophic assay in immature mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 53.4 | Estrogenic activity in uterotrophic assay in immature mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 18.5 | Estrogenic activity in uterotrophic assay in immature mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 25.5 | Estrogenic activity in uterotrophic assay in immature mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 35.8 | Estrogenic activity in uterotrophic assay in immature mice at 50.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 39.5 | Estrogenic activity in uterotrophic assay in immature mice at 125 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 42.6 | Estrogenic activity in uterotrophic assay in immature mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 45.7 | Estrogenic activity in uterotrophic assay in immature mice at 50.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 51 | Estrogenic activity in uterotrophic assay in immature mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 52.3 | Estrogenic activity in uterotrophic assay in immature mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Effect (functional) | = 53.4 | Estrogenic activity in uterotrophic assay in immature mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 7.2 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 7.2 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 2 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 12.2 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 12.2 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 10.0 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 22 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 10.0 ug | ChEMBL. | 2296015 |
Inhibition (functional) | = 22 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 10.0 ug | ChEMBL. | 2296015 |
Inhibition (functional) | = 25.9 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 50.0 ug subcutaneous dose; p<0.01 | ChEMBL. | 2296015 |
Inhibition (functional) | = 25.9 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 50.0 ug subcutaneous dose; p<0.01 | ChEMBL. | 2296015 |
Inhibition (functional) | = 34.1 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 34.1 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 250 ug subcutaneous dose | ChEMBL. | 2296015 |
Inhibition (functional) | = 42 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 125 ug subcutaneous dose; p<0.01 | ChEMBL. | 2296015 |
Inhibition (functional) | = 42 % | Inhibition of 0.4 ug estrone-stimulated uterine growth in mice at 125 ug subcutaneous dose; p<0.01 | ChEMBL. | 2296015 |
Inhibition (functional) | < 67 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 100 ug | ChEMBL. | 2296015 |
Inhibition (functional) | = 67 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice supplemented with 0.3 mg of TP at 1000.0 ug | ChEMBL. | 2296015 |
Inhibition (functional) | < 67 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 100 ug | ChEMBL. | 2296015 |
Inhibition (functional) | = 67 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice supplemented with 0.3 mg of TP at 1000.0 ug | ChEMBL. | 2296015 |
Inhibition (functional) | < 77 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 1000 ug | ChEMBL. | 2296015 |
Inhibition (functional) | < 77 % | Inhibition of testosterone-stimulated seminal vesicle growth in castrated mice at 1000 ug | ChEMBL. | 2296015 |
RBA (binding) | = 0.23 | Relative binding affinity(RBA) for 50% displacement of [3H]-mibolerone from Androgen receptor compared to testorone | ChEMBL. | 2296015 |
RBA (binding) | = 17 | Relative binding affinity(RBA) for 50% displacement of [3H]-estradiol from Estrogen receptor compared to 17-beta-estradiol | ChEMBL. | 2296015 |
RBA (binding) | = 0.13 | Relative binding affinity(RBA) as ratio of progesterone and compound required to displace [3H]-org 2058 binding to Progesterone receptor by 50% | ChEMBL. | 2296015 |
RBA (binding) | = 0.23 | Relative binding affinity(RBA) for 50% displacement of [3H]-mibolerone from Androgen receptor compared to testorone | ChEMBL. | 2296015 |
RBA (binding) | = 17 | Relative binding affinity(RBA) for 50% displacement of [3H]-estradiol from Estrogen receptor compared to 17-beta-estradiol | ChEMBL. | 2296015 |
Relative seminal vesicle weight (functional) | = 38.3 | Relative effect on seminal vesicle weight in adult and castrated mice at 1000 ug dose | ChEMBL. | 2296015 |
Relative seminal vesicle weight (functional) | = 54.5 | Relative effect on seminal vesicle weight in adult and castrated mice at 100 ug dose | ChEMBL. | 2296015 |
Relative seminal vesicle weight (functional) | = 132 | Relative effect on seminal vesicle weight in adult and castrated mice at 10 ug dose | ChEMBL. | 2296015 |
Relative seminal vesicle weight (functional) | = 187.4 | Relative effect on seminal vesicle weight in adult and castrated mice supplemented with 0.3 mg TP at 1000 ug dose | ChEMBL. | 2296015 |
T/C (functional) | = 2 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 2 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 4 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 8 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 8 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-5 M | ChEMBL. | 2296015 |
T/C (functional) | = 10 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 10 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 5x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 25 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 25 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 45 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 45 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 45 % | Effect on [3H]-thymidine incorporation into MDA-MB 231 human breast cancer cells at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 45 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 63 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-7M | ChEMBL. | 2296015 |
T/C (functional) | = 63 % | Effect on [3H]-thymidine incorporation into MCF-7 human breast cancer cells at 1x10E-7M | ChEMBL. | 2296015 |
T/C (functional) | = 74 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 74 % | Cytostatic effect on hormone-independent MDA-MB 231 human breast cancer cell proliferation at 1x10E-6M | ChEMBL. | 2296015 |
T/C (functional) | = 80 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-7M | ChEMBL. | 2296015 |
T/C (functional) | = 80 % | Effect on hormone-dependent MCF-7 human breast cancer cell proliferation at 1x10E-7M | ChEMBL. | 2296015 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.